頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma):治療薬開発パイプライン動向2015

◆英語タイトル:Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2015
◆発行会社/調査会社:DelveInsight
◆商品コード:DELVP501601
◆発行日:2015年版(※最新版はお問い合わせください)
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:60以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(納品まで約3営業日)
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥138,750見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥444,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の市場調査資料のご購入、委託調査サービスに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma):治療薬開発パイプライン動向2015]についてメールでお問い合わせはこちら
本調査レポートでは、世界における頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma)の治療薬開発パイプライン動向について調査・分析し、企業別開発中の治療薬、各臨床試験段階における製品リスト及び比較分析、薬剤候補のプロファイル、治療薬の評価、開発中止又は開発休止中の製品リスト等をお届けしています。また、頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma)治療薬開発に取り組んでいる企業情報も提供しています。(※本レポートはご注文を頂いてから、最新データに更新して納品しているため、正確なページ数を明記しておりません。)

・頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma)の概要

・頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma)のパイプライン製品概要

・企業別開発中の治療薬

・後期治験段階の製品(Filed & Phase III):比較分析

・中期治験段階の製品(Phase II):比較分析

・初期治験段階の製品(Phase I & IND):比較分析

・前臨床段階の製品:比較分析

・薬剤候補のプロファイル

・頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 投与経路別
  - 分子の種類別

・開発が中止された製品リスト

・開発休止中の製品リスト

・頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma)治療薬開発に取り組んでいる企業リスト

・図表一覧
*** レポート概要(サマリー)***

SUMMARY
DelveInsight’s,“ Recurrent Head And Neck Cancer Squamous Cell Carcinoma-Pipeline Insights, 2015”, report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Recurrent Head And Neck Cancer Squamous Cell Carcinoma. This report provides information on the therapeutic development based on the Recurrent Head And Neck Cancer Squamous Cell Carcinoma dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

[Data Sources]

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated Indication.


Scope
• The report provides a snapshot of the global therapeutic landscape of Recurrent Head And Neck Cancer Squamous Cell Carcinoma
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


*** レポート目次(コンテンツ)***

Table of Contents
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Overview
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Therapeutics
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Development by Companies
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Late Stage Products (Filed and Phase III)
– Comparative Analysis
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Mid Clinical Stage Products (Phase II)
– Comparative Analysis
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Early Clinical Stage Products (Phase I and IND Filed)
– Comparative Analysis
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Discovery and Pre-Clinical Stage Products
– Comparative Analysis
• Drug Candidate Profiles
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Therapeutics Assessment
– Assessment by Monotherapy Products
– Assessment by Combination Products
– Assessment by Route of Administration
– Assessment by Molecule Type
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Discontinued Products
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma – Dormant Products
• Companies Involved in Therapeutics Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Monotherapy Products
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Combination Products
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Route of Administration
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Stage and Route of Administration
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Molecule Type
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Stage and Molecule Type
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics – Discontinued Products
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics – Dormant Products
• Products under Development by Companies, 2015


List of Figures
• Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Monotherapy Products
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Combination Products
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Route of Administration
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Stage and Route of Administration
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Molecule Type
• Recurrent Head And Neck Cancer Squamous Cell Carcinoma Assessment by Stage and Molecule Type


*** レポートのキーワード ***

頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma)、治療薬(医薬品、薬剤)、製薬企業、研究開発、治験、製品パイプライン

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※H&Iグローバルリサーチは調査サービスを通じて、お客様の海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをご提供しております。
※当市場調査資料"頭部・頚部の再発性扁平上皮癌(Recurrent Head And Neck Cancer Squamous Cell Carcinoma):治療薬開発パイプライン動向2015"は"DelveInsight社"が調査・発行しており、H&Iグローバルリサーチが販売します。お気軽にお問い合わせください。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。